GFAP concentrations were elevated in higher levels of amyloid neuropathology (CERAD frequent, Thal phase 4 or higher), but the fold-change over higher ADNC and Braak stages was modest compared to p-tau217 (eFigure 6 in Supplement 1). This evidence concerns the gene GFAP and amyloidosis.